Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $15.94 to $16.89
• 50-Day Range: $8.73 to $16.33
• 52-Week Range: $8.58 to $22.50
• Volume: 1.80 million shs
• Average Volume: 2.25 million shs
• Market Capitalization: $1.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.00
• Consensus Rating: Buy

Syndax Pharmaceuticals Stock Analysis - MarketRank™

Syndax Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 224th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Syndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Syndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syndax Pharmaceuticals is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syndax Pharmaceuticals is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syndax Pharmaceuticals has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

23.93% of the outstanding shares of Syndax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 13.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syndax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syndax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

23.93% of the outstanding shares of Syndax Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Syndax Pharmaceuticals has recently decreased by 13.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.26

News Sentiment

Syndax Pharmaceuticals has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.13 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Syndax Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 5 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $684,527.00 in company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.

SNDX Stock Analysis - Frequently Asked Questions

How have SNDX shares performed this year?

Syndax Pharmaceuticals' stock was trading at $13.22 at the beginning of the year. Since then, SNDX shares have increased by 22.8% and is now trading at $16.2350.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Monday, August, 4th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.18. The company's revenue was up 984.5% compared to the same quarter last year.
Read the conference call transcript.

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Top institutional shareholders of Syndax Pharmaceuticals include Bank of America Corp DE (4.46%), Stempoint Capital LP (2.75%), Franklin Resources Inc. (2.74%) and Geode Capital Management LLC (2.38%). Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher, William Meury, Pierre Legault, Briggs Morrison and Peter Ordentlich.
View institutional ownership trends.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 9/02/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNDX
• CIK: 1395937
• Web: www.syndax.com
• Phone: (781) 419-1400
• Fax: 781-419-1420
• Employees: 110
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Syndax Pharmaceuticals: $38.00
• High Price Target: $56.00
• Low Price Target: $17.00
• Potential Upside/Downside: +134.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$318.76 million
• Net Margins: -428.48%
• Pretax Margin: -428.48%
• Return on Equity: -130.47%
• Return on Assets: -56.12%

Debt

• Debt-to-Equity Ratio: 2.06
• Current Ratio: 4.71
• Quick Ratio: 4.55

Sales & Book Value

• Annual Sales: $23.68 million
• Price / Sales: 59.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 4.80

Miscellaneous

• Outstanding Shares: 86,140,000
• Free Float: 82,610,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 0.72